Objective To investigate the correlation between hypothyroidism during pregnancy and hypertensive disorders of pregnancy(HDP) and its impact on pregnancy outcomes. Methods A retrospective analysis was conducted on the clinical data of 152 pregnant women admitted to Fujian Provincial Corps Hospital of Chinese People’s Armed Police Force from October 2020 to December 2023. They were divided into three groups based on thyroid function in the early stage of pregnancy: a normal group (n=60), a subclinical hypothyroidism group (SCH, n=66), and an overt hypothyroidism group (OH, n=26).The thyroid function, blood pressure, blood lipid, blood glucose levels as well as the incidence of HDP and gestational diabetes mellitus(GDM) were compared among the three groups. Logistic regression was used to analyze factors influencing adverse pregnancy outcomes. Results Compared with the normal group, the SCH and OH groups had significantly higher thyroid stimulating hormone (TSH), systolic/diastolic blood pressure, fasting/2-hour postprandial blood glucose, total cholesterol, and low-density lipoprotein cholesterol (LDL-C), and lower high-density lipoprotein cholesterol (HDL-C), with statistically significant differences (P<0.05). Logistic regression showed that the risk of HDP in the SCH and OH groups was 3.82 times (OR=3.816, 95% CI: 1.311-11.114) and 4.05 times (OR=4.053, 95% CI: 1.149-14.296) than that of the normal group, respectively, and the risk of GDM was 3.77 times (OR=3.769, 95% CI: 1.166-12.188) and 5.16 times (OR=5.158, 95% CI: 1.359-19.583) than that of the normal group, respectively. After standardized treatment with levothyroxine, the incidence of adverse pregnancy outcomes (preterm birth, premature rupture of membranes, etc.) in the SCH and OH groups (19.70% and 26.92%) was not statistically different from that in the normal group (13.33%) (P=0.308). After adjusting for metabolic indicators, the risks tended to be insignificant (SCH a group: OR=0.391, 95% CI: 0.103-1.481, P=0.167; OH group: OR=0.892, 95% CI: 0.221-3.593, P=0.872). Conclusions Hypothyroidism during pregnancy significantly elevates the risk of HDP and GDM. Early-stage screening of thyroid function, intensified monitoring of blood pressure and metabolic parameters, and standardized levothyroxine treatment can effectively improve pregnancy outcomes.
Key words
pregnancy /
hypothyroidism /
hypertensive disorders of pregnancy /
correlation /
pregnancy outcome
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Centers for Disease Control and Prevention. Pregnancy mortality surveillance system[EB/OL].(2023-03-23)[2024-03-09].https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-system.html.
[2] 杨 宁,李玉明.宽严相济:孕期血压管理[J].中华高血压杂志,2019,27(1):2-4.
[3] 国家卫生健康委员会.2022中国卫生健康统计年鉴[EB/OL].(2023-05-17)[2024-03-09]. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb.shtml.
[4] 李晨阳.甲状腺疾病与妊娠并发症[J].中国计划生育和妇产科, 2023,15(2):23-26,35.
[5] Li Y,Teng D,Ba J,et al.Efficacy and safety of long-term universal salt iodization on thyroid disorders: epidemiological evidence from 31 provinces of mainland China[J].Thyroid,2020,30(4):568-579.
[6] 王 莉,李凤英.甲状腺功能减退症对妊娠晚期孕妇血糖、血脂代谢及妊娠结局的影响[J].中国妇幼保健,2018,33(14):3147-3150.
[7] 《妊娠和产后甲状腺疾病诊治指南》(第2版)编撰委员会,中华医学会内分泌学分会,中华医学会围产医学分会.妊娠和产后甲状腺疾病诊治指南(第2 版)[J].中华内分泌代谢杂志,2019,35(8):636-665.
[8] 孔北华,马 丁,段 涛.妇产科学[M].10版.北京:人民卫生出版社,2024:87.
[9] US Preventive Services Task Force,Barry M J,Nicholsonw K,et al.Screening for hypertensive disorders of pregnancy:US preventive services task force final recommendation statement[J].JAMA,2023,330(11):1074-1082.
[10] 中华医学会妇产科学分会妊娠期高血压疾病学组.妊娠期高血压疾病诊治指南(2020)[J].中华妇产科杂志,2020,55(4):227-238.
[11] 《孕产期甲状腺疾病防治管理指南》编撰委员会,中华医学会内分泌学分会,中华预防医学会妇女保健分会.孕产期甲状腺疾病防治管理指南[J].中华内分泌代谢杂志,2022,38(7):539-551.
[12] 中华医学会妇产科学分会妊娠期高血压疾病学组.妊娠期血压管理中国专家共识(2021)[J].中华妇产科杂志,2021,56(11):737-745.
[13] 中华医学会妇产科学分会产科学组,中华医学会围产医学分会,中国妇幼保健协会妊娠合并糖尿病专业委员会.妊娠期高血糖诊治指南(2022)[第一部分][J].中华妇产科杂志,2022,57(1):3-12.
[14] Spyridoula M,Raphael M,Yao X,et al.Variation in treatment practices for subclinical hypothyroidism in pregnancy:US national assessment[J].J Clin Endocrinol Metab,2019,104(9):3893-3901.
[15] 喻昆林,宫 芸,于南南,等.昆明地区不同妊娠期甲状腺激素水平参考范围的建立及临床分析[J].现代妇产科进展,2020,29(1):51-54.
[16] 王 进,胡晞江,蔡文倩.湖北省不同孕期妇女甲状腺功能参考值范围的建立及应用[J].中华地方病学杂志,2019,38(3):189-192.
[17] Sterrett M. Maternal and fetal thyroid physiology[J].Clin Obstet Gynecol,2019,62(2):302-307.
[18] Yuan N,Sun J,Li Z,et al.Relationship between anti-thyroid peroxidase antibody positivity and pregnancy-related and fetal outcomes in Euthyroid women: a single-center cohort study[J].BMC Pregnancy Childbirth,2020,20(1):491-500.
[19] DeLeo S,Pearce E N.Autoimmune thyroid disease during pregnancy[J].Lancet Diabetes Endocrinol, 2018,6(7):575-586.
[20] 季 滢,朱 蓓,马宗丽.妊娠期妇女甲状腺功能减退与亚甲状腺功能减退对妊娠结局和胎儿影响的分析对比研究[J].中国医药导报,2021,18(3):116-119.
[21] 车 蕾,项国谦.妊娠期甲状腺功能异常与妊娠期糖尿病和妊娠期高血压疾病的关系[J].中国妇幼保健,2024,39(14):2592-2595.
[22] 代巧云,关 婷,张宏光,等.育龄女性促甲状腺激素水平异常与血压升高的关联研究[J].中华内分泌代谢杂志,2021,37(12):1075-1081.
[23] 许 波,江碧薇,袁雪蓉,等.妊娠期甲状腺功能异常与妊娠期糖尿病、高血压的患病风险分析[J].中国计划生育学杂志,2019,27(4):479-483.
[24] 车力凡,刘 瑶,张 玲,等.甲状腺功能指标在不同孕期妊娠期糖尿病和妊娠期高血压疾病中的表达水平及意义[J].中国临床实用医学,2021,12(1):8-11.
[25] 刘成程,田 丽,李健美.妊娠期甲状腺功能减退症与母体糖脂代谢紊乱的相关性和对妊娠结局的影响[J].中国妇幼保健,2021,36(17):3947-3949.
[26] 赵志佳,陈筵明,吴怡梵,等.甲状腺相关激素与妊娠期糖尿病的研究进展[J].中国细胞生物学学报,2022,44(3):477-483.
[27] 叶可君,彭梦佳,戴 洁,等.妊娠期糖尿病与妊娠期高血压疾病患者甲状腺功能变化情况与临床干预研究[J].中国妇幼保健,2018,33(14):3142-3146.
[28] 黄贤恩,陈良苗,陈 翔.妊娠晚期甲状腺功能减退对母体血糖、血脂水平影响及母婴预后分析[J].中国妇幼健康研究,2017,28(3):299-302.
[29] Kaftan A N,Naser F H,Enaya M A.Changes of certain metabolic and cardiovascular markers fructosamine,H-FABP and Lipoprotein(a) in patients with hypothyroidism[J].Med Arch,2021,75(1):11-15.
[30] 金 姣,陈亚军.妊娠期甲状腺功能减退症与GDM、PIH的关系及其对妊娠结局的影响[J].检验医学与临床,2020,17(23):3463-3465.
[31] John H,Lazarus,M D,Jonathan P B,et al.Antenatal thyroid screening and childhood cognitive function[J].NEJM,2012,366(6):493-501.
PDF(1059 KB)
